Trial Profile
A Phase I Open-label, Multi-center Dose-escalation Study to Determine the Maximum Tolerated Dose (MTD) and Dose Limiting Toxicity of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Gimatecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis
- 30 Apr 2012 Actual patient number is 120 according to ClinicalTrials.gov.
- 30 Apr 2012 Actual patient number is 120 according to ClinicalTrials.gov.
- 30 Apr 2012 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.